ISN Journal summaries on sefaxersen for IgAN and the effect of climate change on kidney disease
Kidney International® A single-arm phase 2 trial of an investigational RNA therapeutic targeting complement factor B (sefaxersen) for treatment of IgA nephropathy IgA nephropathy (IgAN) involves activation of the complement alternative pathway, contributing to kidney inflammation and disease progression. In this global, open-label phase 2 trial, patients with biopsy-confirmed IgAN received sefaxersen, an antisense inhibitor of complement factor B, to...